MOESM2 of Tafenoquine treatment of Plasmodium vivax malaria: suggestive evidence that CYP2D6 reduced metabolism is not associated with relapse in the Phase 2b DETECTIVE trial

Pamela St Jean (3557882)
Zhengyu Xue (3557891)
Nick Carter (3557885)
Gavin Koh (3557879)
Stephan Duparc (209857)
Maxine Taylor (1503283)
Claire Beaumont (1405708)
Alejandro Llanos-Cuentas (80989)
Ronnatrai Rueangweerayut (232866)
Srivicha Krudsood (17232)
Justin Green (3557876)
Justin Rubio (3557888)

Publication date

February 2016

DOI

10.6084/m9.figshare.c.3637778_d1.v1

Abstract

Additional file 2. The percentage of intermediate metabolizers by treatment. The percentage of subjects who were intermediate metabolizers (IM) with error bars representing the standard error of the mean

Extracted data

We use cookies to provide a better user experience.

Data Protection

MOESM2 of Tafenoquine treatment of Plasmodium vivax malaria: suggestive evidence that CYP2D6 reduced metabolism is not associated with relapse in the Phase 2b DETECTIVE trial

Abstract

Extracted data

MOESM2 of Tafenoquine treatment of Plasmodium vivax malaria: suggestive evidence that CYP2D6 reduced metabolism is not associated with relapse in the Phase 2b DETECTIVE trial

Abstract

Extracted data

Related items

Related items